Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies

ONCOLOGY (United States)

Volumn 26, Issue 9, 2012, Pages

  Mathisen, Michael S ^a   Jabbour, Elias ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLINATUMOMAB; CALICHEAMICIN; CD19 ANTIBODY; CD20 ANTIBODY; CD22 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMATINIB; INOTUZUMAB OZOGAMICIN; MEMBRANE ANTIGEN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; NELARABINE; OFATUMUMAB; PEGYLATED ASPARAGINASE; PONATINIB; PREDNISONE; RITUXIMAB; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG HYPERSENSITIVITY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOFIBRINOGENEMIA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PANCREATITIS; PH; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 84874641569     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Pui CH, Campana D, Pei D, et al. Treating childhood leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-41.
3. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG 2993 trial. Br J Haematol. 2012;157:463-71.
4. Thomas DA, OBrien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880-9.
5. Alvarnas JC, Brown PA, Aoun P, et al. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia. Version 1.2012. Available at www.NCCN.org.
6. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2464-71.
7. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-37.
8. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1,500 patients from the international ALL trial: MRC UKALL XII/ECOG 2993. Blood. 2005;106:3760-67.
9. Kantarjian H, Thomas D, OBrien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788-801.
10. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:21-9.
11. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Childrens Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646-54.
12. Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive post-induction treatment: a report from the Childrens Oncology Group. J Clin Oncol. 2009; 27:5189-94.
13. Rytting ME, Thomas DA, Jabbour E, et al. Adolescent and young adult patients with acute lymphoblastic leukemia (ALL) treated with modified Augmented Berlin-Frankfurt-Muenster (ABFM) therapy. Blood (ASH Annual Meeting Abstracts). 2011;118:1527.
14. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.
15. Gokbuget N, Baumann A, Beck J, et al. Peg-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) study 07/2003. Blood (AHS Annual Meeting Abstracts). 2010;116:494.
16. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegaspariginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237-53.
17. Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52:325-27.
18. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high-risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood (ASH Annual Meeting Abstracts). 2010;116:170.
19. Arzerra (ofatumumab) Package Insert. Research Triangle Park, NC. GlaxoSmithKline. September 2011.
20. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood. 2011;118:5126-29.
21. HyperCVAD plus ofatumumab in CD20-positive acute lymphoblastic leukemia. Available at www.clinicaltrials.gov (NCT01363128). Accessed June 28, 2012.
22. Hoelzer D, Gokbuget N. T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma. 2009;9 Suppl 3:S214-21.
23. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukemia: a subtype of very high risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147-56.
24. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157-63.
25. Neumann M, Coskun E, Benlasfer O, et al. High rate of FLT3 mutations in adult ETP-ALL. Blood (ASH Annual Meeting Abstracts). 2010;116:1031.
26. Arranon (nelarabine) Package Insert. Research Triangle Park, NC. GlaxoSmithKline. 12/2011.
27. Gandhi V, Keating MJ, Bate G, Kirkpatrick P. Nelarabine. Nat Rev Drug Discov. 2006;5:17-18.
28. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010; 28:3644-52.
29. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
30. Hu Y, Liu Y, Pelletier S, et al. Requirement of SRC kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453-61.
31. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114:5426-5435.
32. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DACISION). Blood. 2012;119:1123-29.
33. Ravandi F, OBrien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070-77.
34. Rousselot P, Cayuela JM, Hayette S, et al. Dasatinib and low-intensity chemotherapy for first-line treatment in elderly patients with de novo Philadelphia-positive ALL (EWALL-PH-01): kinetic of response, resistance, and prognostic significance. Blood (ASH Annual Meeting Abstracts). 2010;116:172.
35. OHare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401-12.
36. HyperCVAD and ponatinib in Ph-positive and/or BCR-ABL positive acute lymphoblastic leukemia. Available at www.clinicaltrials.gov (NCT01424982). Accessed June 28, 2012.
37. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG 2993). Blood. 2008;111:1827-33.
38. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment of adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075-86.
39. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532-43.
40. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153-62.
41. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG2993 study. Blood. 2007;109:944-50.
42. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010; 116:5568-74.
43. Faderl S, Thomas DA, OBrien S, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11:54-59.
44. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL XII/ECOG 2993 study. Blood. 2007;109:944-50.
45. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95:589-96.
46. Clolar (clofarabine) Package Insert. Cambridge, MA. Genzyme Corporation. 2/2012.
47. Pigneaux A, Sauvezie M, Vey N, et al. Clofarabine combinations in adults with refractory/relapsed acute lymphoblastic leukemia (ALL): a GRAAL report. Blood (ASH Annual Meeting Abstracts). 2011;118:2586.
48. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043-49.
49. Barba P, Sampol A, Calbacho M, et al. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma: the Spanish experience. Am J Hematol. 2012;87:631-34.
50. Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504-11.
51. Pharmacokinetic and pharmacodynamics study of nelarabine in patients with relapsed/refractory lymphoid malignancies. Available at www.clinicaltrials.gov (NCT 01094860). Accessed July 14, 2012.
52. Portell CA, Advani A. Antibody therapy for acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2012;7:153-9.
53. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 2008;68:6300-5.
54. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkins lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085-93.
55. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403-11.
56. Jabbour E, OBrien SM, Thomas DA, et al. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, given weekly, for refractory relapse acute lymphoblastic leukemia. J Clin Oncol. 30, 2012 (suppl; abstract 6501).
57. Raponi S, De Propis MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098-107.
58. Fitzgerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 2011;71:6300-09.
59. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-98.
60. Topp M, Goekbuget N, Zugmaier G, et al. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. J Clin Oncol. 2012;30 (suppl; abstr 6500).
61. Dworzak MN, Schumich A, Printz D, et al. CD20-up regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed therapy. Blood. 2008;112:3982-88.
62. Inotuzumab ozogamicin in elderly acute lymphoblastic leukemia. Available at www.clinicaltrials.gov (NCT 01371630). Accessed July 14, 2012.
63. Fernando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program. 2009;353-61.